Concerning tau isoform specificity, most tau ligands were initially developed to target the tau fibrils present in Alzheimer’s disease (i.e., paired helical filaments) [243], which differ from those found in Parkinsonian tauopathies (4-repeat tau fibrils) [244, 245]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.